Fertility preservation and management of gonadal failure associated with lymphoma therapy

Howell, Simon; Shalet, Stephen M

doi:10.1007/s11912-002-0039-6

Cited by 60 publications

(35 citation statements)

References 93 publications

(88 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Discussion of fertility issues and sperm banking should be addressed in the appropriate circumstances. 57 Bone marrow biopsy is usually included in the workup for all patients with NHL. Bone marrow involvement occurs in 39% of low-grade, 36% of intermediate-grade, and 18% of high-grade lymphomas.…”

Section: Workupmentioning

confidence: 99%

Non-Hodgkin’s Lymphomas

Ad¹,

Js²,

Rh³

et al. 2010

J Natl Compr Canc Netw

223

View full text Add to dashboard Cite

OverviewNon-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating in B-, T-, or natural killer (NK) lymphocytes. In the United States, B-cell lymphomas represent 80% to 85% of all cases, with 15% to 20% being T-cell lymphomas; NK lymphomas are very rare. In 2009, an estimated 65,980 new cases of NHL will be diagnosed and 19,500 will die of the disease.1 NHL is the sixth leading site of new cancer cases among men and fifth among women, accounting for 4% to 5% of new cancer cases and 3% to 4% of cancer-related deaths. Non-Hodgkin's Lymphomas Clinical Practice Guidelines in OncologyKey Words NCCN Clinical Practice Guidelines, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma, cutaneous T-cell lymphoma, mycosis fungoides, Sézary syndrome, marginal zone lymphoma, mucosaassociated lymphoid tissue lymphoma, diagnosis, treatment, hematopathology, immunohistochemistry, treatment guidelines, staging evaluation, lymphoma pathology (JNCCN 2010;8:288-334) NCCN Categories of Evidence and ConsensusCategory 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN consensus. Category 2A: The recommendation is based on lowerlevel evidence and there is uniform NCCN consensus. Category 2B: The recommendation is based on lowerlevel evidence and there is nonuniform NCCN consensus (but no major disagreement). Category 3: The recommendation is based on any level of evidence but reflects major disagreement. Please NoteThese guidelines are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no representation or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their applications or use in any way.These guidelines are copyrighted by the National Comprehensive Cancer Network. All rights reserved. These guidelines and the illustrations herein may not be reproduced in any form without the express written permission of the NCCN © 2010. Disclosures for the NCCN Non-Hodgkin's Lymphomas Guidelines PanelAt the beginning of each NCCN guidelines panel meeting, panel members disclosed any financial support they have received from industry. Through 2008, this information was published in an aggregate statement in JNCCN and online. Furthering NCCN's commitment to public transparency, this disclosure process has now been expanded by listing all potential conflicts of interest respective to each individual expert panel member.Individual disclosures for the NCCN Non-Hodgkin's Lymphomas Guidelines Panel members can be found on page 334. (To view the most recent version of these guideli...

show abstract

Section: Workupmentioning

confidence: 99%

Non-Hodgkin’s Lymphomas

Ad¹,

Js²,

Rh³

et al. 2010

J Natl Compr Canc Netw

223

View full text Add to dashboard Cite

show abstract

“…11 Potential for recovery with increasing periods of time since HSCT has been reported, 2 but if damage to the ovaries has occurred once, it is usually thought to be irreversible and can lead to infertility and amenorrhoea. 12 Even in pre-menarcheal girls, an ovarian dosage of 15 Gy can lead to irreversible fertility impairment. 13 Impaired fertility in females seems to be closely related to the destruction of oocytes, which also impairs sex steroid production.…”

Section: Introductionmentioning

confidence: 99%

Fertility after allogeneic haematopoietic stem cell transplantation in childhood and adolescence

Borgmann‐Staudt

Rendtorff

Reinmuth

et al. 2011

Bone Marrow Transplant

155

123

View full text Add to dashboard Cite

Infertility is a major late effect in patients receiving haematopoietic stem cell transplantation (HSCT). The aim of this study was to determine the proportion of patients having fertility impairment after allogeneic HSCT in childhood/adolescence and to identify the potential risk factors. Treatment and fertility data of paediatric patients with malignant and non-malignant diseases treated with allogeneic HSCT between 2000 and 2005 were collected from seven European centres. Data were obtained for 138 female and 206 male patients after a median follow-up of 6 years (range 3-12). The patients' median age was 13 years (range 4-28) at the time of years at the time of the enquiry. Seven children were born to the overall group, all at term and healthy. Fertility impairment was suspected in 69% males and 83% females. Start of treatment at age X13 years was a risk factor in females (odds ratio (OR) 4.7; 95% confidence interval (CI), 1.5 to 14.9), whereas pre-pubertal therapy was a risk factor in males (OR 0.4; 95% CI, 0.2 to 0.8). The major treatment-related risk factors were BU in females (OR 47.4; 95% CI, 5.4 to 418.1) and TBI in males (OR 7.7; 95% CI, 2.3 to 25.4). In light of the significant proportion of HSCT patients reviewed with impaired fertility, fertility conservation procedures should be considered for all patients undergoing HSCT, particularly those receiving TBI or BU-based preparative regimens.

show abstract

“…Большинство авторов указывает, что ве-роятность развития недостаточности яични-ков вследствие ХТ повышается с возрастом: частота развития недостаточности яичников существенно ниже у женщин, получивших ХТ в возрасте до 25 лет [5,16,24,28,30,37,50]. По нашим данным (С. В.…”

Section: Wwwmalignanttumorsorgunclassified

Reproductive function in women after radio- and chemoradiotherapy of Hodgkin's lymphoma and health status of born children.

et al. 2015

View full text Add to dashboard Cite

. Кроме того, облучены: парааортальная область (26 чел.), пахово-подвздошные области (6 чел.), экстранодальные очаги (16 чел.). Применение химиотерапии не сопровождалось гормональной защитой яичников. Беременность у большинства женщин протекала нормально. Выкидыши предшество-вали родам у 6 чел. Беременность у 1 женщины прервана в 24 недели в связи с синдромом Денди-Уокера у плода, у 1 была внутриутробная гибель плода из-за патологии мочевыводящей системы. У 338 женщин в возрасте 18-38 (ме-диана-24) лет было 406 родов. Период после лечения до родов: 10 мес.-17 лет (медиана -3,4). Большинство родов были срочными -391 (96,3 %), самостоятельными -380 (93,6 %). Родилось 411 детей. Двое были мертворожденными, 4 умерло в первые дни жизни. Доношенным был 387 (94 %) ребенок. Рост и вес не отличались от нормы. Большинство детей родилось здоровыми, в дальнейшем их физическое, психическое состояние, частота ихарактер перенесенных заболеваний не отличались от таковых в обычной популяции, за исключением развития у 3 их них ЛХ. Врожденная па-тология выявлена у 12 детей (микроцефалия -2, гидроцефалия-1, порок сердца -3, сенсорная тугоухость -2, рас-щелина верхнего неба -1, фиброзная дисплазия кости -1, множественные экзостозы костей -1, отсутствие почки -1). Общее количество врожденной патологии с учетом 2 случаев прерывания беременности в связи с патологией плода -14 на 413 (3,4 %). Второе поколение родившихся составило 23 чел. Рецидив ЛХ развился после родов у 14 женщин. Установлено: беременность после лечения ЛХ в большинстве случаев протекает нормально, не приводя к развитию рецидива ЛХ при полной ремиссии длительностью более 2 лет. Большинство детей рождается здоровыми.

show abstract

Fertility preservation and management of gonadal failure associated with lymphoma therapy

Cited by 60 publications

References 93 publications

Non-Hodgkin’s Lymphomas

Non-Hodgkin’s Lymphomas

Fertility after allogeneic haematopoietic stem cell transplantation in childhood and adolescence

Reproductive function in women after radio- and chemoradiotherapy of Hodgkin's lymphoma and health status of born children.

Contact Info

Product

Resources

About